daily interruption of sedatives

PreclinicalSmall molecule

daily interruption of sedatives is one of 4 small molecule programs targeting Critically Ill. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Critically IllCompleted

Critically IllPreclinical

Completed

Competition

Competitive Landscape

3 competitors in Critically Ill

#DrugCompanyPhaseTrials

Reglan

IIstituto Clinico Humanitas

Preclinical

2 2

Androgel

RRepros Therapeutics Inc.

Phase 2

1 3

daily interruption of sedatives

RRadboud University Medical Center

Preclinical

1 4

Isotonic

IIstanbul University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Critically Ill1 trial

Effects of Daily Interruption of Sedatives in Critically Ill Children

Completed·RRadboud University Medical Center·N/A·NCT00441506·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for daily interruption of sedatives. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — daily interruption of sedatives compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for daily interruption of sedatives. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Radboud University Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: RRadboud University Medical Center

daily interruption of sedatives

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Critically Ill1 trial

References

Drug Info

Quick Facts

Related News